Korro Bio (KRRO) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Korro Bio is the larger company by market cap ($125.0 million vs $117.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRRO | RTSN |
|---|---|---|
| Share price | $8.49 | $14.07 |
| Market cap | $125.02M | $117.23M |
| 1-day change | -8.81% | +15.23% |
| YTD return | +5.99% | — |
| 1-year return | -79.86% | — |
| 5-year return | -97.48% | — |
| EPS (TTM) | $-9.88 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.39M | — |
| Revenue growth (YoY) | +181.46% | — |
| Net income (latest FY) | $-117.26M | — |
| Operating margin | -1906.37% | — |
| Net margin | -1834.48% | — |
| 52-week high | $48.70 | $14.97 |
| 52-week low | $5.20 | $9.66 |
| Distance from 52-week high | -82.57% | -6.02% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +137.93% | — |
| Average volume | 151.92K | 252.97K |
| Shares outstanding | 14.73M | 8.33M |
| Employees | 57 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
KRRO vs RTSN FAQ
Which is bigger, Korro Bio or Retension Pharmaceuticals?
Korro Bio (KRRO) is larger, with a market capitalization of $125.02M compared with $117.23M for Retension Pharmaceuticals (RTSN).
Are Korro Bio and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.